Literature DB >> 18154797

Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy.

Nicholas G Smedira1, Bruce W Lytle, Harry M Lever, Jeevanantham Rajeswaran, Gita Krishnaswamy, Ryan K Kaple, Diana O W Dolney, Eugene H Blackstone.   

Abstract

BACKGROUND: Septal myectomy is the gold-standard therapy for hypertrophic obstructive cardiomyopathy (HOCM). However, it is being challenged by a less-invasive alternative: alcohol septal ablation. This study examined the clinical effectiveness and risks of isolated septal myectomy for HOCM.
METHODS: From January 1994 to January 2005, 323 patients underwent isolated septal myectomy (mean age 50 +/- 14 years, 53% male). Preoperative septal thickness was 2.3 +/- 0.46 cm and peak left ventricular outflow tract (LVOT) gradient 68 +/- 43 mm Hg. Effectiveness of myectomy was assessed by echocardiography, sudden death, and functional limitation, early risks by intraoperative and postoperative complications, and late risks by follow-up for HOMC-related reoperation, heart block, and all-cause mortality (mean 3.6 +/- 2.8 years, 1,152 patient-years, 10% followed > or = 8 years).
RESULTS: Myectomy was effective, resulting in sustained decrease in septal thickness and LVOT gradient, absence of sudden death, and improved functional status. Early in-hospital morbidity was low, with no hospital deaths; two iatrogenic ventricular septal defects were repaired uneventfully, and 22 pacemakers were required for heart block. In the intermediate term, 10 patients required HOCM-related reoperations (4 redo myectomies, 6 mitral valve procedures), with 92% freedom from reoperation at eight years. Seventy-nine percent were free of pacemakers by 8 years, and survival was 90%, equivalent to that of the general population.
CONCLUSIONS: Isolated septal myectomy is effective in eliminating LVOT obstruction and sudden death and in improving functional status, with low operative morbidity and mortality. Few reoperations are required late and outcomes are excellent. It should be considered the treatment of choice for HOCM.

Entities:  

Mesh:

Year:  2008        PMID: 18154797     DOI: 10.1016/j.athoracsur.2007.07.063

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  35 in total

Review 1.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

2.  Reoperative myectomy via the left ventricular apex in a patient with hypertrophic obstructive cardiomyopathy.

Authors:  Patrick Oellers; Shuab Omer; Gregor Makosch; Ramon Kumar; Haroon-Ur Rashid; Joseph P Navarijo; David A Ott
Journal:  Tex Heart Inst J       Date:  2010

3.  Surgery for hypertrophic cardiomyopathy.

Authors:  James J Wu; Michael Seco; Caroline Medi; Chris Semsarian; David R Richmond; Joseph A Dearani; Hartzell V Schaff; Michael J Byrom; Paul G Bannon
Journal:  Biophys Rev       Date:  2015-01-10

4.  Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience.

Authors:  Hassan Rastegar; Griffin Boll; Ethan J Rowin; Noreen Dolan; Catherine Carroll; James E Udelson; Wendy Wang; Philip Carpino; Barry J Maron; Martin S Maron; Frederick Y Chen
Journal:  Ann Cardiothorac Surg       Date:  2017-07

5.  Letter to the Editor: Contemporary Screening and Treatment of Hypertrophic Cardiomyopathy.

Authors:  Fahed Darmoch; Mohamad Soud; Yasser Al-Khadra; Homam Moussa Pacha; M Chadi Alraies
Journal:  Ochsner J       Date:  2018

6.  In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction.

Authors:  Dae-Hee Kim; Mark D Handschumacher; Robert A Levine; Yun-Sil Choi; Yun Jeong Kim; Sung-Cheol Yun; Jong-Min Song; Duk-Hyun Kang; Jae-Kwan Song
Journal:  Circulation       Date:  2010-09-13       Impact factor: 29.690

7.  Diastolic leading to systolic anterior motion: new technology reveals physiology.

Authors:  Robert A Levine; Ehud Schwammenthal; Jae-Kwan Song
Journal:  J Am Coll Cardiol       Date:  2014-11-03       Impact factor: 24.094

Review 8.  The diagnosis and treatment of hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Martin Farr; Detlef Hering; Dieter Horstkotte; Lothar Faber
Journal:  Dtsch Arztebl Int       Date:  2011-04-01       Impact factor: 5.594

Review 9.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

10.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.